Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of GAP-134 Administered Intravenously

NCT00510029 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

72

Enrollment

INDUSTRY

Sponsor class

Conditions

Arrhythmia

Interventions

DRUG: GAP-134

Sponsor

Wyeth is now a wholly owned subsidiary of Pfizer